Minitablets
Minitablets: Enhancing Safety and Palatability for Pediatric Medicines
Gus LaBella
Mikart
PAO-09-24-CL-01Aug 30, 2024
Drug Delivery
Nanocarriers to Overcome the Blood–Brain Barrier (BBB)
Serene Lee
Nice Insight
PAO-09-24-NI-01Aug 30, 2024
Developability
Assessing Developability and Designing Advanceable Formulations from the Start
Nazar Elkarim, Ph.D.
Mikart
PAO-09-24-CL-02Aug 26, 2024
Developability
Streamlining the Path to Approval with Developability and Pre-Formulation Platforms
Andrea Hawe
Coriolis Pharma
PAO-07-24-CL-11Aug 01, 2024
CRDO
Partnering with Scientific Excellence to De-Risk and Accelerate Drug Development
Silvia Steyrer-Gruber
Coriolis Pharma
PAO-07-24-CL-05Jul 16, 2024
Liquid Suspensions
Beyond Pills: the Rise of Liquid Suspensions for Complex Formulations
Gus LaBella
Mikart
PAO-07-24-CL-04Jul 09, 2024
Monoclonal Antibodies
Coriolis Pharma Launches U.S. Entity Alongside Innovative Drug Product Platform Service Offerings for Monoclonal Antibodies
Coriolis Pharma
PR-05-24-NI-02Jun 18, 2024
Lipid Nanoparticles
Feasibility Studies and cGMP Design Supporting Continuous Lipid Nanoparticle Manufacturing
Jim Ziogas
DIANT Pharma
PAO-05-24-CL-03May 30, 2024
mRNA Innovations
Technology Advances Needed to Drive Future mRNA Growth
Hagen Richter, Ph.D.
PAO-04-24-CL-04Apr 15, 2024
mRNA–LNP Manufacturing
The Innovators Bringing Continuous Manufacturing to Lipid Nanoparticles
Antonio Costa, Ph.D.; William Pasek
DIANT Pharma
PAO-03-24-CL-08Mar 18, 2024
Advanceability
Right from the Start: Designing Advanceable Formulations and Processes at Phase I
Serán Bioscience
PAO-02-24-CL-09Feb 26, 2024
Biologics Formulation
Successful Formulation Development for Biologics Using a Unique Biophysical Prediction and Screening Platform
Pawel Stanczak, Ph.D.
Tanvex CDMO
PAO-02-24-CL-02Feb 15, 2024
CDMO
Maximizing Outsourcing Benefits for Virtual Pharma Companies
William Kazimier
Tedor Pharma Services
PAO-09-23-CL-08Jan 11, 2024
Lipid Nanoparticles
Facilitating Development and Scale-Up of Nanoparticle Drug Products with an End-to-End Adaptable Manufacturing Platform
Antonio Costa, Ph.D.
DIANT Pharma
PAO-10-23-CL-03Nov 01, 2023
Failing Fast
Maximizing Resources and Potential for Success by Failing Fast
Nazar Elkarim, Ph.D.
Mikart
PAO-10-23-CL-02Oct 23, 2023
Formulation
Addressing Swallowing and Palatability Issues with Patient-Friendly Dosage Forms
Gus LaBella
Mikart
PAO-09-23-CL-04Oct 03, 2023
CDMO
Redesigning ANDA or Novel Drug Products at All Stages for the U.S. Market
Tedor Pharma Services
PAO-08-23-CL-06Sep 26, 2023
Viscosity Reduction
Viscosity Reduction with An Excipient Platform and Feasibility Testing Service
Alana Gouveia
MilliporeSigma
PAO-08-23-CL-03Aug 10, 2023
Alternative Excipient
Preparing Today for a Potential Ban on Titanium Dioxide in Pharmaceutical Drug Products
Almut von der Brelie
MilliporeSigma
PAO-08-23-CL-01Aug 03, 2023
New Integrated mRNA Offering
Building on Experience and Investing in an Integrated mRNA Offering
Jessica Madigan; Normand Blais
BIOVECTRA
PAO-07-23-CL-03Jul 31, 2023